Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 1.06B | 835.61M | 1.09B | 672.65M | 881.14M |
Gross Profit | 5.95M | 3.01M | 4.70M | -486.00K | -79.57M |
EBITDA | -18.02M | -18.12M | -15.44M | -19.07M | -95.42M |
Net Income | -21.00M | -20.84M | -17.46M | -21.20M | -94.81M |
Balance Sheet | |||||
Total Assets | 614.60M | 628.86M | 620.41M | 640.56M | 710.60M |
Cash, Cash Equivalents and Short-Term Investments | 8.20M | 24.35M | 37.58M | 26.65M | 54.37M |
Total Debt | 30.63M | 34.00M | 9.00M | 15.37M | 21.12M |
Total Liabilities | 132.28M | 125.61M | 96.32M | 98.91M | 148.38M |
Stockholders Equity | 482.31M | 503.31M | 524.15M | 541.70M | 562.20M |
Cash Flow | |||||
Free Cash Flow | -11.05M | -40.50M | 15.46M | -19.72M | 3.91M |
Operating Cash Flow | -11.05M | -40.49M | 15.46M | -19.72M | 3.91M |
Investing Cash Flow | 3.59M | -58.00K | -219.00K | 137.00K | 12.00K |
Financing Cash Flow | -8.68M | 26.85M | -7.05M | -9.08M | -758.00K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
61 Neutral | $36.05B | 6.66 | -10.61% | 1.86% | 8.68% | -8.81% | |
39 Underperform | HK$199.75M | ― | -4.27% | ― | 25.25% | 0.74% | |
― | $57.64M | ― | -13.04% | ― | ― | ― | |
― | €32.93M | 13.84 | -6.99% | ― | ― | ― | |
― | €27.69M | ― | -8.93% | ― | ― | ― | |
73 Outperform | HK$350.29M | 10.18 | 4.39% | 9.84% | -0.88% | 7.28% | |
59 Neutral | HK$2.48B | 73.31 | 15.73% | 0.41% | 11.29% | 40.42% |
Vital Innovations Holdings Limited held its Annual General Meeting on June 18, 2025, where shareholders voted on several resolutions. The company successfully passed resolutions related to receiving and considering financial statements, re-electing directors, and appointing auditors. However, resolutions granting the board general mandates to issue additional shares, repurchase shares, and extend mandates were not passed, indicating shareholder concerns over potential dilution and capital management strategies.
Vital Innovations Holdings Ltd. has outlined the terms of reference for its Nomination Committee, which is responsible for recommending board composition and evaluating potential directors. The committee’s duties include assessing board diversity and independence, and ensuring alignment with corporate strategy, which could impact the company’s governance and strategic direction.